Advertisement

Search Results

Advertisement



Article Topics

Your search for Chase Doyle and Caroline Helwick matches 2 pages

Showing 1 - 2


Expert Point of View: Clifford Hudis, MD, Shanu Modi, MD, and Richard Gelber, PhD

Discussant Clifford Hudis, MD, Chief of Breast Medicine Service at Memorial Sloan Kettering Cancer Center, New York, highlighted neratinib’s benefits while also advocating caution in interpreting the results due to incomplete data, the serious side effect of diarrhea, and the potentially...

breast cancer

Neratinib Improves Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer

Patients with early-stage HER2-positive breast cancer who received neratinib as extended adjuvant therapy demonstrated improved invasive disease–free survival, with an absolute benefit of 2.3% at 2 years.1 However, these results of the ExteNET trial, previously presented at the 2015 ASCO Annual...

Advertisement

Advertisement



Advertisement